CMS kept Bridge outreach limited while Lilly and Novo Nordisk advertised GLP-1s

Medicare's GLP-1 Bridge opened on July 1, 2026, giving eligible Part D beneficiaries a $50 copay for a monthly supply of certain GLP-1 medicines for chronic weight management ^[2]. CMS chose not to promote the launch heavily. A CMS official said at a press briefing that the agency did limited public outreach ahead of the July launch because beneficiaries act on information when they can actually use it, and that more promotion would follow as the program matured ^[1].

The Bridge is a temporary CMS demonstration scheduled to run through December 31, 2027 ^[2]. It works outside the usual Part D path: CMS set up a separate nationwide process for prior authorization, pharmacy claims and payment ^[2]. Beneficiaries must meet eligibility and clinical criteria, and their providers must submit the required prior authorization information ^[2].

With CMS quiet at the start, the drugmakers did much of the advertising. Eli Lilly and Novo Nordisk ran their own Bridge promotions, including social video and television commercials for Foundayo (orforglipron) and Zepbound (tirzepatide) ^[1]. A Wegovy (semaglutide) commercial cited the $50 price without naming the program ^[1]. The Patient Advocate Foundation promoted an explainer about the Bridge to a newsletter that reaches nearly 400,000 people ^[1].

Several basic numbers are still missing. Enrollment totals, the number of prescriptions filled under the Bridge, the complete list of covered medicines, and how much CMS or the manufacturers spent on promotion have not been disclosed. CMS has not given a date for the broader promotion the official described ^[1].

Why it matters for patients

Where people first hear about the $50 price can shape what they understand about the program. An ad that mentions the price but not the Bridge does not explain eligibility rules, clinical criteria or the prior authorization step that providers must complete ^[1][2]. That matters because the $50 copay applies only to beneficiaries who qualify and whose prescriptions are approved through that process ^[2].

The Obesity Action Coalition, which is tracking the program, notes that beneficiaries, providers and pharmacies are all learning a new system at the same time, and that coverage only fulfills its promise when people can actually get the medicine ^[2]. The group also says it is too early to draw sweeping conclusions about how well the Bridge is working ^[2].

The program is temporary. It is scheduled to end December 31, 2027, and it has not been reported whether it will be extended ^[2]. CMS has said the demonstration will produce information about GLP-1 use that can inform future Medicare policy, so how the first months go could affect later coverage decisions ^[2].

What happens next

• The Bridge continues through December 31, 2027, with the $50 monthly copay for eligible beneficiaries ^[2].
• CMS said more promotion would follow as the program matured, but no date or budget has been disclosed ^[1].
• CMS expects the demonstration to generate utilization data to inform future Medicare policy ^[2].
• Enrollment figures and any decision about extending the program past 2027 have not been reported.